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Abstract
Introduction In the nonobese diabetic (NOD) mouse model of
Sjögren's syndrome, lymphocytic infiltration is preceded by an
accumulation of dendritic cells in the submandibular glands
(SMGs). NOD mice also exhibit an increased frequency of
mature, fractalkine receptor (CX3C chemokine receptor
[CX3CR]1) expressing monocytes, which are considered to be
precursors for tissue dendritic cells. To unravel further the role
played by fractalkine-CX3CR1 interactions in the salivary gland
inflammation, we studied the expression of fractalkine in NOD
SMGs.
Methods We studied protein expression using Western blot
analysis of whole tissue lysates. Protease activity was measured
in salivary gland tissue lysates using fluorimetric substrates.
Digestive capacity of enzymes was determined by in vitro
incubation of recombinant enzyme and fractalkine, followed by
protein staining and Western blot.
Results Fractalkine was detected in salivary glands of both
NOD and control mice at all ages. Western blot analysis
showed fractalkine cleavage with increasing age, which was
more pronounced in NOD mice. This cleavage resulted in a
decrease in the 31 kDa form of the protein, and the generation
of an approximately 19 kDa band. Furthermore, in NOD animals
older than 15 weeks, we noted the presence of a unique
approximately 17 kDa fragment. This cleavage was organ
specific, because it did not occur in brain or pancreas.
Increased gelatinase and α-secretase activity were detected in
NOD SMG and contributed to cleavage of the 31 kDa protein.
Because aberrant cleavage products may induce autoimmunity,
we studied the presence of autoantibodies against fractalkine.
Indeed, NOD mice exhibited significantly more antibodies
against fractalkine than did control animals.
Conclusion These data indicate that aberrant proteolytic activity
in the NOD SMG results in increased fractalkine cleavage and
generation of a unique fractalkine fragment. This specific
cleavage may contribute to autoimmunity.
Introduction
The nonobese diabetic (NOD) mouse is a frequently used
spontaneous animal model for the development of Sjögren's
syndrome (SjS). Similar to SjS patients, these mice develop
lymphocytic infiltrates in their salivary glands, which leads to
gland destruction and decreased salivary flow. The develop-
ment of infiltrates is preceded by an accumulation of dendritic
cells (DCs). Given the key role played by DCs in the initiation
of immune responses, their accumulation as one of the early
events in SjS indicates that DCs are involved in the pathogen-
esis of the disease [1,2]. The precise cause of DC accumula-
tion remains to be elucidated, but alterations in monocytes,
which are considered to be a precursor population for DCs,
have been described in the NOD mouse [3,4]. In particular,
the subset of Ly-6Clow monocytes is significantly expanded in
the NOD circulation [3]. This subset is thought to be a mature
population that preferentially develops into tissue DCs [5],
suggesting a link between these cells and the DC accumula-
tion observed in the salivary gland of NOD mice.
Apart from the low expression of Ly-6C, the mature monocyte
subset is further characterized by low expression of CC chem-
okine receptors 1 and 2, and high expression of CX3C chem-
okine receptor (CX3CR)1, the fractalkine receptor [6].Page 1 of 7
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first described in brain tissue [7,8]. It differs from other chem-
okines not only in its structure and relatively large size, but also
in the fact that it occurs in both membrane bound and soluble
forms. The membrane bound form functions as an adhesion
molecule, whereas the soluble form is strongly chemotactic for
monocytes and T cells [9,10].
Given the increase in mature Ly-6Clow monocytes in the NOD
circulation, their propensity to develop into DCs and the impor-
tance of fractalkine in chemoattraction of Ly-6Clow monocytes,
we studied the expression of fractalkine in NOD salivary
glands. Although fractalkine was present in salivary glands of
both NOD and control mice, a unique fragment of the protein
was observed in NOD mice. Such a fragment may contribute
to disruption of tolerance to fractalkine, resulting in an autoim-
mune response. Indeed, an anti-fractalkine antibody response
in the NOD mouse is identified here.
Materials and methods
Animals
NOD/LTj mice were bred in our own facility. Mice were tested
for diabetes twice weekly and excluded from experiments
when positive. C57BL/6 and BALB/c mice were obtained
from Harlan (Horst, The Netherlands). All mice were housed
under specific pathogen-free conditions and were fed stand-
ard chow and water ad libitum. Female mice aged 5 to 25
weeks were used in all experiments. All experimental proce-
dures were approved by the Erasmus University Animal Ethical
Committee.
Tissue lysates and protease activity
Submandibular glands (SMGs) and pancreases were
removed and cleared of adipose tissue and lymph nodes. Tis-
sue was placed in phosphate-buffered saline, or phosphate-
buffered saline containing a protease inhibitor cocktail (Com-
plete mini protease inhibitor tablets; Roche, Woerden, The
Netherlands) where indicated, and homogenized by mechani-
cal disruption followed by ultrasound sonification. Finally,
lysates were cleared by centrifugation. Caspase-3 and gelati-
nase (matrix metalloprotease [MMP]-2/MMP-9) activity were
measured using EnzCheck assay kits (Invitrogen, Eugene, OR,
USA) in accordance with the manufacturer's instructions. α-
Secretase activity was measured using a fluorogenic sub-
strate (10 μg/reaction, alpha-secretase substrate II; Merck,
Whitehouse Station, NJ, USA), as indicated by the manufac-
turer. All results are shown as arbitrary units relative to the total
amount of protein, as measured by Bradford analysis (BioRad,
Hercules, CA, USA).
Western blot
Protein content of lysates was measured by Bradford analysis
(BioRad) and 50 μg of each lysate was loaded onto a 15%
SDS-PAGE gel and run under reducing conditions. For deter-
mination of protein size, the Kaleidoscope-prestained stand-
ard was used (BioRad). Afterward, protein was transferred to
an Immobilon-P membrane (Millipore, Billerica, MA, USA).
Membranes were then incubated with anti-fractalkine antibody
(C-20, 1 μg/ml; Santa Cruz, Santa Cruz, CA, USA) followed
by Donkey-anti-Goat-HRP (80 ng/ml; Santa Cruz). Expression
was detected by enhanced chemiluminescence (ECL) analy-
sis (Amersham, Piscataway, NJ, USA). For detection of
autoantibodies, tissue lysates known to contain specific forms
of fractalkine were loaded onto a 15% SDS-PAGE gel. After
transfer, membranes were incubated with IgG purified from
mouse serum by protein G-column separation or with total
serum. This was followed by Rabbit-anti-mouse-HRP
(1:20,000; Dako, Glostrup, Denmark) and ECL analysis.
In vitro digestion assay
MMP-2 (65 ng/reaction; Chemicon, Temecula, CA, USA) and
MMP-9 (140 ng/reaction; R&D Systems Inc., Minneapolis,
MN, USA) were activated by 1 mmol/l AMPA in 10 mmol/l
CaCl2, 100 mmol/l NaCl, and 50 mmol/l (Tris/HCl pH 7.5).
Caspase-3 (10 ng/reaction; Gentaur, Brussels, Belgium) was
diluted in 10 mmol/l PIPES, 2 mmol/l EDTA, 0.1% CHAPS
and 5 mmol/l DTT (pH 7.4). A disintegrin and metalloprotease
domain (ADAM)-10 and ADAM-17 (both 500 ng/reaction;
R&D systems Inc.) were diluted in 50 mmol/l HEPES, 5 μmol/
l ZnCl2, 0.01% Brij-0 [pH 7.5]). Enzyme activity was confirmed
by fluorimetric assay as described above. Active enzyme was
then incubated with brain lysate (20 μg protein/reaction) for 2
hours at 37°C. Digestion was stopped by adding reducing
sample buffer and heating to 99°C. Protein analysis was car-
ried out using Western blot as described above.
Statistical analysis
Bars represent mean, and error bars represent standard devi-
ation. For comparison of means Student's t-test was used, and
for comparison of frequencies Fisher's exact test was calcu-
lated, both using SPSS software (SPSS Inc., Chicago, IL,
USA).
Results
Fractalkine is present in NOD submandibular glands and 
cleaved with increasing age
To determine the presence of fractalkine at the protein level,
expression was studied in SMG tissue lysates by Western
blot. Because expression of fractalkine has been clearly
described in normal brain [11,12], this was used as a refer-
ence sample. Analysis of SMG tissue from young (age 5
weeks) NOD mice revealed expression of the protein at a
molecular weight similar to that observed in brain lysates (31
kDa). However, when salivary glands of 15-week-old mice
were studied, additional bands were observed at about 19
kDa and about 17 kDa (Figure 1a). Also, the 31 kDa band was
less intense or even undetectable at these time points, indicat-
ing cleavage of fractalkine with increasing age in the salivary
glands of NOD mice.Page 2 of 7
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When control mice were studied, the profile of fractalkine
cleavage differed markedly from that in NOD mice. At age 5
weeks no clear differences were found, with the expression of
only the 31 kDa form of the protein in both control strains. At
10 weeks, the approximately 19 kDa band began to appear in
C57BL/6 and BALB/c mice. However, whereas expression of
the 31 kDa band frequently disappeared in NOD mice at this
age, this band was still clearly present in the control strains
(Figure 1b). The additional approximiately 17 kDa form of frac-
talkine, which was found in NOD mice, never appeared in
either C57BL/6 or BALB/c mice at any time point up to 20
weeks (Figure 1b). These results indicate that the profile of the
cleavage process differs between NOD and control strains,
and that the specific cleavage in NOD SMG results in the gen-
eration of a unique fractalkine fragment in the NOD mouse.
Cleavage of fractalkine does not occur in NOD pancreas
The NOD mouse not only develops sialoadenitis but also
autoimmune insulitis. Similar to the salivary glands, lym-
phocytic infiltration in the pancreas is preceded by an accumu-
lation of DCs. Because the sialoadenitis and pancreatitis
observed in NOD mice are usually considered to be the result
of at least partly overlapping defects, expression of fractalkine
in the pancreas was studied and compared with that of the
SMG. In both NOD and control mice, expression of the 31 kDa
form of fractalkine was detected at all ages tested. However,
smaller products were not observed at any age, either in NOD
or in the control strains (Figure 1c). This indicates that the
increase in protease activity is SMG specific.
ADAM-17 induces fractalkine cleavage, but ADAM-10 
and caspase-3 do not
Altered protein breakdown has previously been described in
the SMG of NOD mice, a specific example being the autoan-
tigen α-fodrin, and this was linked to caspase-3 activity [13-
15]. Therefore, caspase-3 activity was measured in whole
Figure 1
Altered fractalkine cleavage in NOD salivary gland. Whole tissue lysates were prepared in phosphate-buffered saline (PBS) supplemented with pro-
tease inhibitor by mechanical homogenization followed by sonification. Lysates were then analysed by Western blotting. A representative picture of 
six individual experiments is shown. (a) Submandibular gland (SMGs) of 5-, 10- and 15-week-old nonobese diabetic (NOD) mice. (b) SMGs of 10-
week-old (left) and 20-week-old (right) NOD, C57BL/6 and Balb/c mice. (c) Pancreas of 5- and 20-week-old NOD and Balb/c mice. Numbers rep-
resent mass (kDa), as determined using a molecular weight marker.Page 3 of 7
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all ages, no increase in caspase-3 activity was observed in the
NOD mouse (Figure 2a). Furthermore, when brain lysates con-
taining the 31 kDa form of fractalkine were incubated with
recombinant caspase-3, no digestion of fractalkine was
observed (Figure 2a [insert]).
Another family of proteases involved in regulating fractalkine
levels are the so-called α-secretases. These include ADAM-10
and ADAM-17, which have been shown to cleave fractalkine
under steady-state and inflammatory conditions, respectively
[16,17]. When measured in whole salivary gland lysates, α-
secretase activity was significantly increased in NOD mice
from the age of 15 weeks onward (Figure 2b). When incu-
bated with brain lysate in vitro, ADAM-17 but not ADAM-10
was capable of cleaving 31 kDa fractalkine. However, the
approximately 19 and 17 kDa bands did not appear (Figure 2b
[insert]), and neither did any smaller fractalkine fragments
down to 6 kDa (data not shown). This indicates that although
ADAM-17 may contribute to the fractalkine cleavage observed
in NOD SMG, other proteases probably result in the genera-
tion of the approximately 19 kDa and 17 kDa fragments.
MMP-9 activity leads to cleavage of 31 kDa fractalkine
Increased expression of MMP-9 has been described in the sal-
ivary glands of SjS patients, and RNA levels of both MMP-2
and MMP-9 are increased in the SMG of NOD mice [18-20].
Because fractalkine has been shown to be a ligand for MMP-
2 [21], increased activity of these metalloproteases may be
involved in the altered proteolysis of fractalkine. When meas-
ured in whole salivary gland lysates, gelatinase (combined
MMP-2 and MMP-9) activity was increased in NOD mice aged
10 weeks – the time point at which the increased cleavage of
fractalkine in the NOD first becomes apparent (Figure 3a). Fur-
thermore, incubation of brain lysates with recombinant MMP-
9, but not with MMP-2, resulted in a clear reduction in the 31
kDa form of fractalkine (Figure 3b). However, the approxi-
mately 19 and 17 kDa bands did not appear in this experiment,
and neither did any smaller fragments down to 6 kDa (data not
shown). This indicates that in addition to MMP-9, other pro-
teases are likely to contribute to the fractalkine cleavage
observed in vivo.
Presence of autoantibodies against fractalkine in NOD
Altered proteolysis of α-fodrin in NOD results in the generation
of an autoantigen and the formation of autoantibodies [14].
Therefore, the occurrence of autoantibodies against fractalk-
ine was studied by testing the reactivity of mouse serum with
blotted brain lysate containing the 31 kDa form of fractalkine.
In the serum of young (5 weeks) animals, reactivity against the
31 kDa protein could not be detected. However, in the serum
of animals older than 15 weeks, antibodies against a protein
running at 31 kDa were detected in 10 out of 14 NOD mice
(Figure 4). In control animals, this was the case in significantly
fewer (one out of six; P < 0.05). Similar results were obtained
with purified IgG and total serum (data not shown). Fractalkine
specificity of the anti-31 kDa band was confirmed by blotting
against recombinant fractalkine (data not shown). These
results indicate that fractalkine indeed becomes an autoanti-
gen in the NOD mouse.
Discussion
NOD mice exhibit an abnormal breakdown of fractalkine in sal-
ivary glands, which results in the generation of a unique frag-
ment. This breakdown did not occur in pancreas, indicating
that the phenomenon is organ specific and not a result of local
inflammation. Altered proteolytic cleavage in NOD salivary
glands has previously been described for α-fodrin and parotid
secretory protein [13,14,22,23]. In the case of α-fodrin, prote-
olysis is caused by the apoptotic enzyme caspase-3 [13].
Figure 2
ADAM-17 but not caspase-3 cleaves 31 kDa fractalkine. (a) Caspase-
3 and (b) α-secretase activities were measured in tissue lysates pre-
pared in phosphate-buffered saline without protease inhibitors using a 
fluorimetric assay. Bars represent mean, error bars represent standard 
deviation (n = 5). * P < 0.05. Recombinant mouse caspase-3 (panel a) 
and a disintegrin and metalloprotease domain (ADAM)-10 or -17 (panel 
b) were incubated with brain lysate and analysed by Western blotting 
(n = 4). Numbers represent mass (kDa), as determined using a molecu-
lar weight marker.Page 4 of 7
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ages, activity was not increased in NOD compared with con-
trol animals. Furthermore, caspase-3 did not cleave 31 kDa
fractalkine in vitro. Two proteases described to be involved in
the physiological shedding of fractalkine are ADAM-10 and
ADAM-17 [16,17]. However, although the joint activity of
these enzymes did increase in NOD mice at older ages (> 15
weeks) and ADAM-17 was capable of cleaving 31 kDa frac-
talkine in vitro, this did not results in the generation of the
approximately 19 and 17 kDa bands.
Previous reports describe the abnormal breakdown of extra-
cellular matrix components in SjS salivary glands, and this was
linked to increased activity of MMPs [24]. In particular, expres-
sion of MMP-9 has consistently been found to be increased in
salivary glands of SjS patients. In NOD mice, increased
expression of this metalloprotease in SMG was reported in old
(> 20 weeks) animals [18-20,24-27]. Our study shows that
MMP-9 activity has already increased at around 10 weeks of
age, similar to the time point at which cleavage of fractalkine
was first observed. Additionally, MMP-9 has been shown to be
capable of degrading the 31 kDa form of fractalkine. However,
the characteristic approximately 17 and 19 kDa forms did not
appear. When fractalkine was incubated with MMP-9 and ana-
lyzed by total protein staining, neither the approximately 19
and 17 kDa fragments nor smaller fragments were detected
(data not shown). This suggests that MMP-9 cleavage results
in very small fragments, at least in vitro. Hence, although both
ADAM-17 and MMP-9 are involved in the degradation of frac-
talkine, other proteases are likely to be responsible for the gen-
eration of the approximately 19 and 17 kDa fragments in vivo.
Candidates for this function include members of the caspase
family, such as caspase-1 and caspase-11, both of which are
increased in the salivary glands under inflammatory conditions
[28,29]. Also, granzyme B may be involved, because this pro-
tease has been shown to generate antigenic fragments by
cleaving α-fodrin, La protein and muscarinic receptor 3
[30,31], all of which are known autoantigens in SjS.
The precise nature of the fractalkine fragments described in
this study remains to be further elucidated. Attempts to isolate
the fractalkine fragments from SMG lysates were unsuccess-
ful because of the abundant presence of other proteins in the
total gland lysates. However, the antibody used to detect frac-
talkine in this study recognizes the carboxyl-terminal end, indi-
cating that both the approximately 19 and 17 kDa fragments
contain this part of the protein. One hypothesis is that the
approximately 19 and 17 kDa fragments are the remaining
(carboxyl-terminal) fragments after shedding of the amino-ter-
minal part of the protein. This amino-terminal part contains the
Figure 3
MMP-9 cleaves 31 kDa in vitro i  vitro. (a) Gelatinase activity was measured in 
tissue lysates prepared in phosphate-buffered saline without protease 
inhibitors using a fluorimetric assay; bars represent mean, and error 
bars represent standard deviation. *P < 0.05 versus C57BL/6 and 
Balc/c; **P < 0.05 versus C57BL/6 (n = 5). (b) Recombinant mouse 
matrix metalloprotease (MMP)-2 and MMP-9 were incubated with brain 
lysate and analysed by Western blotting (n = 3). Numbers represent 
mass (kDa), as determined using a molecular weight marker.
Figure 4
Autoantibodies against fractalkine are present in NOD mice. Tissue 
lysates prepared in phosphate-buffered saline supplemented with pro-
tease inhibitors were run on an SDS gel and transferred to an Immo-
bilon membrane (Millipore, Billerica, MA, USA). Membranes were then 
incubated with purified IgG from either NOD (N) or Balb/c (Ba) mice. 
Binding of autoantibodies was detected by anti-mouse-HRP and elec-
trochemical luminescence (ECL) analysis. Presence of specific fractalk-
ine fragments in the lysate was detected using a polyclonal anti-
fractalkine antibody (a-Fr). Numbers represent mass (kDa), as deter-
mined using a molecular weight marker.Page 5 of 7
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the circulation and enhance monocyte chemoattraction to the
salivary glands. Previous studies have shown that fractalkine is
indeed a substrate for metalloproteinases, resulting in the gen-
eration of a highly active chemotactic fragment [32]. Interest-
ingly, the fractalkine receptor positive population of Ly-6Clow
monocytes is increased significantly in NOD mice [3]. This
population preferentially develops in tissue DCs [33], and frac-
talkine receptor positive cells resembling DCs were observed
in murine salivary glands (HC Reinecker, personal communi-
cation). This supports the idea of chemotactic fractalkine con-
tributing to the accumulation of DCs in NOD salivary glands.
To investigate further this contribution, it would be interesting
to cross CX3CR1-deficient mice [34] back to the NOD back-
ground, and determine the effect on monocyte infiltration and
DC accumulation.
In the case of α-fodrin, the altered cleavage in pSjS and NOD
salivary glands results in an autoantigenic protein and the gen-
eration of autoantibodies as well as a specific T-cell response
[14,35]. Importantly, when cleavage of α-fodrin is inhibited,
pathology is prevented [36], indicating the significance of this
process. In this study we showed that the abnormal cleavage
of fractalkine is also accompanied by the occurrence of
autoantibodies. In NOD mice, antibodies recognizing 31 kDa
fractalkine were present from about 10 weeks and increased
with age. In control mice, these autoantibodies were found in
significantly fewer animals, and at lower concentrations. It is
tempting to speculate that the abnormal breakdown of frac-
talkine in NOD SMG contributes to a break of tolerance
against this self protein, thus resulting in the formation of
autoantibodies. The source of fractalkine in the NOD SMG
remains to be elucidated, but studies in human salivary gland
show that fractalkine is expressed in glandular epithelium as
well as ductal structures [37]. An anti-fractalkine response
would therefore be targeted directly against the salivary gland
epithelium, and contribute to destruction of the salivary gland
tissue.
Conclusion
Increased proteolytic activity in the salivary gland of NOD mice
leads to the generation of aberrant fractalkine fragments.
These may enhance the ongoing inflammation by functioning
as autoantigens. Furthermore, the enhanced cleavage of frac-
talkine is hypothesized to result in increased chemotaxis. This
dual role for fractalkine in local inflammation in SjS salivary
glands indicates that fractalkine may be an interesting target
for future therapy.
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